Reading the Evidence: What the Study Really Shows
The Arising | November 2026
How to read health research without losing either your curiosity or your judgment.
Begin with the life you want to improve
A health headline arrives with a promise. Better memory. Stronger muscles. A younger biological age. Before deciding whether to believe it, give the promise a more precise shape. What would actually change in someone’s life if the claim were true?
The difference matters. Remembering an appointment, walking to the shops, avoiding a fracture, and moving a laboratory value are different outcomes. Each can be studied carefully. Each answers a different question. A compelling explanation of how an intervention might work cannot fill in a missing result about how people feel or function.
Start with four plain questions: Who was studied? What did they receive? What was the comparison? What happened? Then add a fifth: Over how long? These questions slow a headline down enough to make it useful.
The decision is the best place to begin. A person considering a demanding intervention needs evidence about benefits, harms, inconvenience, and alternatives. A researcher exploring a mechanism may reasonably begin much further upstream. Trouble begins when an answer to the second person’s question is sold as an answer to the first person’s decision.
This issue offers a reading method rather than a treatment plan. It follows three research examples, then turns them into questions you can carry into the next paper, conversation, or appointment. The study summaries were checked against primary publication records and abstracts. They are not comprehensive full-text appraisals.
The outcome is the story
The LIFE trial gives a concrete example. It randomized 1,635 sedentary adults aged 70 to 89 who had physical limitations but could still walk 400 metres. Participants received a structured physical activity program or health education. The primary outcome was losing the ability to walk 400 metres. Over an average 2.6 years, this occurred in 30.1% of the activity group and 35.5% of the education group. The reported hazard ratio was 0.82, with a 95% confidence interval of 0.69 to 0.98. [1]
That is a result about mobility in a defined population. It supports a meaningful, bounded conclusion. It does not establish years of life gained or prove that an intervention reverses biological aging.
Harms deserve the same space as benefits. Serious adverse events were reported in 49.4% of the activity group and 45.7% of the education group; the risk ratio was 1.08, with a 95% confidence interval of 0.98 to 1.20. These are reported events, not proof that the program caused them. [1]
The reading habit is simple: underline the endpoint before you underline the headline. Ask whether the endpoint is something people experience, a measurement believed to predict that experience, or an earlier biological signal. Keep those distinctions visible when you describe the finding to someone else.
When biology moves and the clinical answer does not
A 2026 DHA study makes the distinction especially clear. In a randomized, double-blind trial, 365 adults aged 55 to 80 without dementia, with low dietary DHA intake and at least one dementia risk factor, received DHA or placebo. The primary outcome was a cerebrospinal-fluid fatty-acid ratio at six months. That measure improved with DHA. No treatment differences in cognition or brain volumes were observed over 24 months. Dropout was 38%, mainly attributed to COVID-19. The abstract reported comparable adverse events between groups and no serious adverse events attributed to treatment. [2]
The biochemical result and the clinical uncertainty can coexist. The study showed target engagement. It did not demonstrate the hoped-for cognitive benefit over its follow-up. Nor does that observation settle every possible dose, population, or time horizon. Those broader claims would need their own evidence.
Notice how easy it would be to write two misleading headlines from the same study. One could celebrate delivery to the central nervous system as though better memory followed. Another could declare that every nutritional approach to dementia prevention had failed. Neither keeps the original question intact.
A more useful summary preserves the sequence: what changed biologically, what was measured clinically, what was observed, and what limits the interpretation. That sequence leaves room for discovery while protecting the reader from premature certainty.
Read the comparison, then the missing people
A change from baseline can feel persuasive because it tells a story of improvement. But people and measurements change for many reasons. To judge the intervention, ask what happened in the comparison group over the same period. A before-and-after chart alone cannot tell you how much of the change belongs to treatment.
Randomization helps create comparable groups at the start. The rest of the study still matters: how allocation was concealed, who knew the assignment, how outcomes were measured, whether people followed the assigned treatment, and whether the analysis respected the original plan. CONSORT 2025 provides a reporting framework for randomized trials, including a participant-flow diagram and a 30-item checklist. It helps readers locate essential information; a completed checklist is not a guarantee of a sound trial. [4]
Missing outcomes deserve particular attention. People who leave a trial may differ from those who remain. Ask how many left each group, why they left, and what assumptions were used to handle their missing results. Then ask whether plausible alternative assumptions would change the conclusion. A result can be statistically tidy while the path to that result is uncertain.
For observational research, follow a different set of questions. Were the groups already different before the exposure? Could illness have changed the behavior being studied rather than the other way around? What was measured well enough to adjust for? Statistical adjustment relies on the variables and assumptions in the analysis; it cannot automatically remove every unmeasured difference.
STROBE supports transparent reporting of cohort, case-control, and cross-sectional studies. Its own guidance explicitly cautions that the checklist is not an instrument for evaluating study quality. [5] Use reporting standards to see the study more clearly, then judge the methods and relevance separately.
Give the number its denominator
Imagine a fictional study in which an outcome occurs in 20 of 100 people in the comparison group and 15 of 100 in the intervention group over the same fixed period. The absolute reduction is five percentage points. The relative reduction is 25%. Both describe the same counts. Neither is a complete decision by itself.
The fictional example also shows why starting risk matters. A large-sounding relative change can correspond to a small absolute difference when the outcome is uncommon. Always ask: out of how many people, over what period, and for which event?
The LIFE percentages differ by 5.4 percentage points, calculated from the rounded values in the abstract. That descriptive difference is not the trial’s hazard ratio. A hazard ratio summarizes relative event rates over follow-up under the analysis used; it is not a percentage of extra lifetime. [1] Avoid translating between these quantities as though they were interchangeable.
Uncertainty belongs beside the estimate. A confidence interval describes a range of values compatible with the data and statistical model under its assumptions. It does not assign a 95% probability to this particular interval containing the true effect. A narrow interval can still surround a biased estimate, and a result that misses a statistical threshold may still leave clinically important effects unresolved. [7]
Keep practical importance separate from statistical significance. Ask whether the possible benefit is large enough to matter, whether its uncertainty changes the decision, and whether the burdens and harms are acceptable. A small p-value cannot answer those questions on its own.
Biological age needs a second question
A biological-age score can make research feel unusually personal. A number falls, and the story almost writes itself: time has been gained. But the measurement and the meaning need to be examined separately.
A 2026 methods paper by Borrus and colleagues examined how different epigenetic clocks respond to interventions. The authors proposed looking for responses in reliable principal-component-based clocks, in mortality-trained or pace-of-aging clocks, and across multiple clocks moving in the same direction. Their abstract describes reanalyses, simulations, and longitudinal datasets supporting this framework. [3]
Treat those proposed criteria as a way to scrutinize a measurement result. They do not establish that changing a clock improves health or lengthens life. Agreement among related measurements also should not be mistaken for several independent clinical trials.
For a claim that an intervention made someone biologically younger, ask which clock was used, whether the analysis was planned, how many measures were tested, how repeatable the assay is, and what comparison supports the change. Then ask the question that gives the number its purpose: has this change been shown to predict better outcomes when produced by this intervention?
A promising biomarker can be valuable before that final link is established. It can guide experiments and help researchers understand a mechanism. Keeping its role precise makes that promise more credible.
What a review can, and cannot, settle
A systematic review can gather scattered findings into a more useful picture. It can also combine studies that share the same limitations. The words systematic review or meta-analysis on a cover do not remove the need to inspect what went in.
Look for the question, search dates, inclusion rules, and reasons studies were excluded. Ask whether the underlying studies concern comparable people, interventions, outcomes, and follow-up. A pooled estimate may conceal differences that matter to the person making a decision. Several papers from the same participants should not be treated as several independent confirmations.
PRISMA supplies reporting guidance for systematic reviews, with PRISMA 2020 focused primarily on reviews of intervention effects. [6] It is a useful map of what a transparent report should explain. The credibility of the answer still depends on the evidence and the way the review handles it.
A registry or protocol serves another purpose: it lets readers inspect what researchers planned. Compare planned outcomes with reported outcomes, and look for explained amendments. Registration makes a study easier to examine. A registration entry alone is not evidence that an intervention worked.
For any appealing finding, make room for the next study. Would replication in another setting change confidence? Would longer follow-up answer the unresolved question? Would a patient-important outcome change how a biomarker result should be used? Specific uncertainty is more productive than either blanket enthusiasm or blanket dismissal.
A reading card for the next headline
Before passing a claim along, write one sentence with five parts: In this population, this intervention, compared with this alternative, produced this result, over this period. If one part is missing, look for it before strengthening the conclusion.
Then add the limits. Name the most important uncertainty in ordinary language. Perhaps follow-up was short. Perhaps many participants left. Perhaps the outcome was a laboratory measurement rather than function or illness. Perhaps the finding came from animals, and human benefit remains untested.
Finally, write the decision separately. A study may justify a better question, a discussion with a clinician, a larger trial, or a change in practice when considered with the wider evidence. Those are different next steps. Avoid letting the excitement of a result choose the step for you.
The aim is to become a reader who can remain interested without becoming easily persuaded. Good evidence makes room for revision. Good reading does too. The strongest conclusion is the one that stays close enough to the actual study that a future finding can correct it.
Sources and reading scope
Pahor M, et al. LIFE randomized trial. JAMA. 2014;311:2387-2396. DOI: 10.1001/jama.2014.5616. Primary publication record and abstract.
Yassine HN, et al. CNS target engagement of high-dose DHA supplementation in older adults at risk for dementia. EBioMedicine. 2026;129:106316. DOI: 10.1016/j.ebiom.2026.106316. Primary publication record and abstract.
Borrus DS, et al. When to Trust Epigenetic Clocks: Avoiding False Positives in Aging Interventions. Aging Cell. 2026;25:e70756. DOI: 10.1111/acel.70756. Primary publication record and abstract.
Hopewell S, et al. CONSORT 2025 statement. BMJ. 2025;389:e081123. DOI: 10.1136/bmj-2024-081123. Reporting guideline record and abstract.
STROBE official reporting guidance. Website reviewed.
PRISMA official reporting guidance. Website reviewed.
Greenland S, et al. Statistical tests, P values, confidence intervals, and power: a guide to misinterpretations. European Journal of Epidemiology. 2016;31:337-350. DOI: 10.1007/s10654-016-0149-3. Methods publication record and abstract.
Sources 1-4 and 7 were reviewed at publication-record and abstract level, not as full-text systematic appraisals. Targeted correction/retraction searches for sources 1-3 surfaced no specific notice; this is not an exhaustive correction audit. Educational material, not individual medical advice.